Wednesday, March 22, 2023 | Back issues
Courthouse News Service Courthouse News Service

Investment Strategies

MANHATTAN - An endocrinologist is still awaiting share certificates after investing half a million dollars in Medolife based on its Escozine cancer treatment, derived from the venom of blue scorpions, and its "polarization technology," she claims in a federal complaint.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.